Abstract: A system and method for automatically parallelizing a computer program for multi-threaded execution. A compiler identifies and parallelizes non-DOALL parallel regions, such as loops, within a computer program. The compiler determines enhanced helper thread instructions based upon the main body instructions of the non-DOALL region. These helper thread instructions are inserted ahead of the main body instructions within each of the plurality of threads, rather than within a single main thread. Next, synchronization instructions are inserted in one or more threads such that the main body of work of each thread is performed in a pipelined manner. The helper thread instructions within each thread may reduce the total execution time of each thread.

Abstract: The present invention is directed to compounds of formula I and tautomers and pharmaceutically acceptable salts thereof which are selective inhibitors of JAK. The present invention is also directed to intermediates used in making such compounds, the preparation of such a compound, pharmaceutical compositions containing such a compound, methods of inhibition JAK activity, and methods to prevent or treat a number of conditions mediated at least in part by JAK activity.

Abstract: A compilation method is provided for automated user error correction. The method includes using a compiler driver run by a processor to receive a source file for compilation. With a compiler component invoked by the compiler driver, the method includes identifying an error in the source file such as a linking problem or syntax error in the user's program. The method includes receiving with the compiler driver an error message corresponding to the identified error. With an error corrector module run by the processor, the method includes processing the error message to determine an error correction for the identified error in the source file. The compiler driver modifies the source file based on the error correction and compiles the modified source file with the compiler component.

Abstract: A compilation method is provided for correcting compiler errors that include compiler internal errors and errors produced by running a validation suite. The method includes running a compiler on a computer and storing a set of optimization levels in memory accessible by the compiler. The method includes receiving a source file with the compiler that includes a user-defined optimization level to be used in compiling the source file. The method includes identifying a set of functions within the source file and using compiler components to compile these functions using the original optimization level. When the compiling results in an internal error occurring and being reported for one or more of the functions, the method includes using an optimization adjustment module to process the internal error and assign an adjusted or lower optimization level to the one or more functions and recompiling of these functions again with the lower optimization level.

Abstract: One embodiment of the present invention provides a system that generates code for software scouting the regions of a program. During operation, the system receives source code for a program. The system then compiles the source code. In the first step of the compilation process, the system identifies a first set of loops from a hierarchy of loops in the source code, wherein each loop in the first set of loops contains at least one effective prefetch candidate. Then, from the first set of loops, the system identifies a second set of loops where scout-mode prefetching is profitable. Next, for each loop in the second set of loops, the system produces executable code for a helper-thread which contains a prefetch instruction for each effective prefetch candidate. At runtime the helper-thread is executed in parallel with the main thread in advance of where the main thread is executing to prefetch data items for the main thread.

Abstract: Novel benzamide compounds including their pharmaceutically acceptable isomers, salts, hydrates, solvates and prodrug derivatives having activity against mammalian factor Xa are described. Compositions containing such compounds are also described. The compounds and compositions are useful in vitro or in vivo for preventing or treating coagulation disorders.

Abstract: A method for loop reformulation is provided such that a single exit ill-formed loop (SEIFL) can be reformulated into a reformulated code block that contains a transformed well-formed loop (TWFL). A SEIFL loop is a loop that can exit from the loop body of the loop. After the loop reformulation, the TWFL of the reformulated code block can only exit from the end of the loop. The reformulated code block will replace the SEIFL in the compiler's internal representation (IR) such that a more efficient executable machine code can be generated by optimizing the reformulated compiler's IR.

Abstract: The present invention is directed to compounds of formula (I) and pharmaceutically acceptable salts, esters, and prodrugs thereof which are inhibitors of Factor Xa. The present invention is also directed to intermediates used in making such compounds, pharmaceutical compositions containing such a compound, methods to prevent or treat a number of conditions characterized by undesired thrombosis and methods of inhibiting the coagulation of a blood sample.

Abstract: The present invention is directed to compounds represented by Formula (I) or a pharmaceutically acceptable salt, ester, or prodrug thereof which are inhibitors of Factor Xa. The present invention is also directed to and intermediates used in making such compounds, pharmaceutical compositions containing such compounds, methods to prevent or treat a number of conditions characterized by undesired thrombosis and methods of inhibiting the coagulation of a blood sample.

Abstract: The present invention is directed to compounds of formula (I) and pharmaceutically acceptable salts, esters, and prodrugs thereof which are inhibitors of Factor Xa. The present invention is also directed to intermediates used in making such compounds, pharmaceutical compositions containing such a compound, methods to prevent or treat a number of conditions characterized by undesired thrombosis and methods of inhibiting the coagulation of a blood sample.

Abstract: The present invention is directed to compounds of formula (I) and pharmaceutically acceptable salts, esters, and prodrugs thereof which are inhibitors of Factor Xa. The present invention is also directed to intermediates used in making such compounds, pharmaceutical compositions containing such a compound, methods to prevent or treat a number of conditions characterized by undesired thrombosis and methods of inhibiting the coagulation of a blood sample.

Abstract: A system and method for automatically controlling run-time parallelization of a software application. A buffer is allocated during execution of program code of an application. When a point in program code near a parallelized region is reached, demand information is stored in the buffer in response to reaching a predetermined first checkpoint. Subsequently, the demand information is read from the buffer in response to reaching a predetermined second checkpoint. Allocation information corresponding to the read demand information is computed and stored the in the buffer for the application to later access. The allocation information is read from the buffer in response to reaching a predetermined third checkpoint, and the parallelized region of code is executed in a manner corresponding to the allocation information.

Abstract: A computing system has an amount of shared cache, and performs runtime automatic parallelization wherein when a parallelized loop is encountered, a main thread shares the workload with at least one other non-main thread. A method for providing interprocedural prefetching includes compiling source code to produce compiled code having a main thread including a parallelized loop. Prior to the parallelized loop in the main thread, the main thread includes prefetching instructions for the at least one other non-main thread that shares the workload of the parallelized loop. As a result, the main thread prefetches data into the shared cache for use by the at least one other non-main thread.

Abstract: A system and method for automatic efficient parallelization of code combined with hardware transactional memory support. A software application may contain a transaction synchronization region (TSR) utilizing lock and unlock transaction synchronization function calls for a shared region of memory within a shared memory. The TSR is replaced with two portions of code. The first portion comprises hardware transactional memory primitives in place of lock and unlock function calls. Also, the first portion ensures no other transaction is accessing the shared region without disabling existing hardware transactional memory support. The second portion performs a fail routine, which utilizes lock and unlock transaction synchronization primitives in response to an indication that a failure occurs within said first portion.

Abstract: Novel benzamide compounds including their pharmaceutically acceptable isomers, salts, hydrates, solvates and prodrug derivatives having activity against mammalian factor Xa are described. Compositions containing such compounds are also described. The compound and compositions are useful in vitro or in vivo for preventing or treating coagulation disorders.

Abstract: Novel benzamide compounds including their pharmaceutically acceptable isomers, salts, hydrates, solvates and prodrug derivatives having activity against mammalian factor Xa are described. Compositions containing such compounds are also described. The compounds and compositions are useful in vitro or in vivo for preventing or treating coagulation disorders.

Abstract: Compounds, particularly compounds having spleen tyrosine kinase (Syk) inhibition activity, having the following structure: or a pharmaceutically acceptable salt thereof, wherein R1 is structure (a), (b), (c) or (d): and Ra, Rb, Rc, R2, R3, R4, R5, R6 and R7 are as defined herein. Methods associated with preparation and use of the same, as well as pharmaceutical compositions containing the same, are also disclosed, as well as uses of the same to treat a condition or disorder mediated by a Syk and/or JAK kinase.

Abstract: The present invention is directed to compounds represented by Formula (I) or a pharmaceutically acceptable salt, ester, or prodrug thereof which are inhibitors of Factor Xa. The present invention is also directed to and intermediates used in making such compounds, pharmaceutical compositions containing such compounds, methods to prevent or treat a number of conditions characterized by undesired thrombosis and methods of inhibiting the coagulation of a blood sample.

Abstract: The present invention is directed to compounds represented by Formula I and pharmaceutically acceptable salts, solvates, hydrates, and prodrugs thereof which are inhibitors of Factor Xa. The present invention is also directed to and intermediates used in making such compounds, pharmaceutical compositions containing such compounds, methods to prevent or treat a number of conditions characterized by undesired thrombosis and methods of inhibiting the coagulation of a blood sample.

Abstract: One embodiment of the present invention provides a system that facilitates locked prefetch scheduling in general cyclic regions of a computer program. The system operates by first receiving a source code for the computer program and compiling the source code into intermediate code. The system then performs a trace detection on the intermediate code. Next, the system inserts prefetch instructions and corresponding locks into the intermediate code. Finally, the system generates executable code from the intermediate code, wherein a lock for a given prefetch instruction prevents subsequent prefetches from being issued until the data value returns for the given prefetch instruction.